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T0. Summary 
 
T0.1 Main illicit drug use in Ireland 
At the time of publication there were no new data on the prevalence of illicit drug use in Ireland. 
 
The proportion of cases treated for problem cannabis use (excluding synthetic cannabinoids), as recorded 
in the TDI data, has fluctuated over the reporting period. It decreased from 21.2% in 2004 to a low of 
16.3% in 2007 but since then has increased year-on-year to a peak of 28.9% in 2013. Since then the trend 
has stabilised. 
 
In 2017, there were 1,526 cases treated for problem stimulant use as reported through TDI. Similar to 
previous years, the majority were for problem cocaine use (93.4%). 
 
Data show that in 2017, just under half of all cases (44.9%) reported through TDI were treated for opioids, 
slightly down on 2016 (46.9%). Of those treated for problem opiate use in 2016, heroin comprised the vast 
majority of cases (84.5%), similar to previous years. In 2017 methadone (prescribed or street) was the 
second most common other opioid reported, comprising 6.9% of all treatment entrants for problem opiate 
use. Methadone was responsible for 3.1% of all cases treated. This was followed by codeine, accounting 
for 5.7% of all treatment entrants for problem opiate use. 
 
 
T0.2 The use of illicit drugs with alcohol, tobacco and prescription drugs 
 
See the 2018 National report on drugs for most recent information (Health Research Board. Irish National 
Focal Point to the European Monitoring Centre for Drugs and Drug Addiction 2017). 
 
 
SECTION A.  CANNABIS 
 
 
T1. National profile  
 
T1.1 Prevalence and trends 
T1.1.1 The relative importance of different types of cannabis 
 
At the time of publication there were no new data on the relative importance of different types of cannabis 
in Ireland 
 
 
T1.1.2 Cannabis use in the general population 
 
At the time of publication there were no new data on the prevalence of cannabis use in the general 
population in Ireland. 
 
 
T1.1.3 Cannabis use in schools and other sub-populations 
 
At the time of publication there were no new data on the prevalence of cannabis use in schools and other 
sub-populations in Ireland 
 
 
T1.2 Patterns, treatment and problem/high risk use  
 
T1.2.1 Patterns of Cannabis Use 
 
At the time of publication there were no new data on patterns of cannabis use. 
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T1.2.2 Reducing the demand for cannabis 
 
The proportion of cases treated for problem cannabis use (excluding synthetic cannabinoids), as recorded 
in the TDI data, has fluctuated over the reporting period. It decreased from 21.2% in 2004 to a low of 
16.3% in 2007 but since then has increased year-on-year to a peak of 28.9% in 2013. Since then the trend 
has stabilised, although the proportion dropped slightly in 2017 to 24.6% compared to 26.6% 2016. The 
reason for this slight decrease could be due to changes that took place in the national surveillance 
database in 2017 (see Treatment workbook Section T1.3.3 for further information). 
 
Cannabis was the second most common drug for which all entrants sought treatment, after opiates (mainly 
heroin). For new entrants, in 2011 cannabis replaced opiates as the most common problem drug reported 
to treatment (also see Treatment workbook T1.3).  
 
In 2017, 78.7% of cases reporting cannabis as their main problem drug were male, similar to previous 
years. The mean age was 24 years (males 24 years, females 26 years), similar to previous years. In 2017, 
60.4% were new entrants, similar to previous years.  
 
In 2017, the highest percentage of cases (45.5%) were self-referred (including referral from family, friends, 
no other agency/institution involved), similar to previous years. This was followed by 39.5% who were 
referred by other medical agencies or social services.  
 
Most problem cannabis users access treatment in generic drug treatment services. However, there was 
one drug treatment programme specifically for cannabis which commenced in 2015. The funding for this 
programme ceased in March 2018. 
 
T1.2.3 High Risk Cannabis Use 
 
At the time of publication there were no new data on high risk cannabis use. 
T1.2.4 Synthetic cannabinoids 
 
Since 2009 only a very small number of cases have reported synthetic cannabinoids as their main problem 
drug in the TDI data. In 2017, 35 cases reported a synthetic cannabinoid as a main problem drug 
compared to 47 cases in 2016 and 41 in 2015. It should be noted the type of NPS used by clients 
presenting to treatment is self-reported and the actual drug rarely tested by centres, so it is not possible to 
say with any certainty that what was reported was definitely a synthetic cannabinoid. The type of NPS was 
not specified in a proportion of NPS drugs recorded in the TDI data, and so the true number of synthetic 
cannabinoid users may be under- or over-estimated (also see Section B T1.2.4, and Section D T1.2.4, 
below). These 35 cases are not included in the analysis of problem cannabis users in Section T1.2.2 
above. See also Treatment workbook, Sections T1.3 and T2. 
 
 
SECTION B. STIMULANTS 
 
T1. National profile 
 
T1.1 Prevalence and trends 
T1.1.1 The relative importance of different stimulant drugs 
 
At the time of publication there were no new data on the relative importance of different stimulant drugs in 
Ireland. 
 
T1.1.2 Stimulant Use in the General Population 
 
At the time of publication there were no new data on the prevalence of stimulant use in the general 
population in Ireland 
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T1.1.3 Stimulant use in schools and other sub-populations  
 
At the time of publication there were no new data on the prevalence of stimulant use in schools and other 
sub-populations in Ireland 
 
 
T1.2 Patterns, treatment and problem/high-risk use 
 
T1.2.1 Patterns of stimulant use 
 
At the time of publication there were no new data on the patterns of stimulant use in Ireland. 
 
T1.2.2 Treatment for Stimulants 
 
In 2017, there were 1,526 cases treated for problem stimulant use as reported through TDI. Similar to 
previous years, the majority were for problem cocaine use (93.4%), followed by amphetamine-type 
stimulants (2.5%), ecstasy (2.5%) and then synthetic cathinones (0.6%).  
 
The increase in the number of cases reporting problem stimulant use is solely due to the increase in 
problem cocaine users, as the proportion of cases reporting use of amphetamine-type stimulants, ecstasy 
and synthetic cathinones was lower 2017 compared to 2016.  
In 2017, 80.1% of cases were male, a slight increase on previous years. The mean age was 30 years. Just 
over half (52.7%) of those treated for problem stimulant use had never been treated before. Over the 
period, the proportion of new entrants has shown a downward trend from 62.9% in 2004 to 52.7% in 2017. 
In 2016, the majority of cases were self-referred or referred by family/friends (62.9%).  
 
Cocaine  
Cocaine is the most common drug among the stimulants group that is reported in Ireland. The proportion 
of all cases treated for problem cocaine use increased again in 2017 to 16.8% (compared to 12.2% in 
2016). This is compared to a low of 7.5% in 2004 and compared to the highest level previously recorded of 
13.3%, in 2007.  
 
In 2017, 80.6% of cases treated for problem cocaine use were male and the mean age was 30 years. Just 
over half (52.3%) had never been treated before, similar to 2016. The majority (63.7%) were self-referred 
or referred by family/friends.  
 
Amphetamine-type stimulants 
Amphetamine-type stimulants including ecstasy, BZP and other unknown/unspecified stimulants, represent 
only a small proportion of all cases seeking treatment for problem drug use in Ireland. In 2017, 1.1% of 
cases reported this group of drugs. The proportion decreased continuously year-on-year from 3.5% in 
2004 to 1.2% in 2013. Since 2013 the proportion appears to have stabilised. 
 
In 2017, 71.6% of problem amphetamine-type stimulant users were male. In 2017, 58.9% of those treated 
for problem amphetamine-type stimulant use have never been treated before. Small numbers in this 
groups means that trends are difficult to interpret. Given this, the proportion of new cases treated for 
amphetamine-type stimulants has fluctuated between a high of 74% and a low of 40.2% in 2016. 
 
The majority of problem stimulant users access treatment within generic addiction services. There are very 
few stimulant-specific programmes (see Drug Treatment workbook). 
 
T1.2.3 High Risk Stimulant Use 
 
At the time of publication there were no new data on high risk stimulant use in Ireland. 
 
T1.2.4 Synthetic Cathinones 
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Since 2009 only a very small number of cases have reported synthetic cathinones as their main problem 
drug. It should be noted that the type of NPS used by clients presenting for treatment is self-reported and 
the actual drug is rarely tested by treatment centres. Therefore it is not possible to say with certainty that 
what was reported was definitely a synthetic cathinone. In a proportion of cases the type of NPS was not 
specified, so the true number of synthetic cathinone users may be under- or over-estimated. 
 
Synthetic cathinones first appeared in treatment data in 2009 so no information is available before that 
time. The proportion of cases treated for this type of drug peaked in 2010 at 1.5% of all treatment 
episodes, dropping to 0.1% in 2017. Please note that the annual number of small numbers reporting 
synthetic cathinones makes analysis unreliable 
 
T1.2.5 Injecting and other routes of administration 
 
In 2017, 9.7% of cases accessing drug treatment for any stimulant reported ever injecting (not necessarily 
the main problem drug). However, the proportion reporting injecting of the stimulant as the current main 
problem drug was much lower, at 1.4%. As with previous years the most common route of administration 
was sniffing/snorting (78.2%) similar to previous years. 
 
T1.2.6 Infectious diseases 
 
For information regarding drug-related infectious diseases in Ireland, see Harms and Harm Reduction 
workbook Section T1.3. 
 
 
T2. New developments 
 
T2.1 New developments in the use of stimulants 
 
At the time of publication there were no new data on new developments in the use of stimulants in Ireland. 
 
 
SECTION C. HEROIN AND OTHER OPIOIDS 
 
T1. National profile 
 
T1.1 Prevalence and trends 
 
T1.1.1 The relative importance of different opioid drugs 
 
At the time of publication there were no new data on the relative importance of different opioid drugs in 
Ireland 
 
T1.1.2 Estimates of opioid use in the general population 
 
At the time of publication there were no new data on the prevalence of opioid use in the general population 
in Ireland. 
T1.1.3 Estimates of Opioid Use in Sub-populations 
 
At the time of publication there were no new data on the prevalence of opioid use in sub-populations in 
Ireland. 
 
T1.2 Patterns, treatment and problem/high risk use  
T1.2.1 Patterns of opioid use 
 
At the time of publication there were no new data on the patterns of opioid use. 
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T1.2.2 Treatment for heroin and other opioids 
 
All opioids 
Data show that in 2017, just under half of all cases (44.9%) reported through TDI were treated for opioids, 
slightly down on 2016 (46.9%). Of those treated for problem opiate use in 2016, heroin comprised the vast 
majority of cases (84.5%), similar to previous years. However, it should be noted that the results for 
opiates cases in 2016 could be due to changes that took place in the national surveillance database in 
2017 (see Treatment workbook Section T1.3.3 for further information). 
 
Problem heroin use  
Problem heroin use represented 37.9% of all cases treated in 2017 and 84.5% of all opioids treated. The 
proportion of cases treated for problem heroin use has fluctuated over the reporting period, rising from 
59.7% in 2004 to a peak in 2006 of 60.3%. In 2017, the downward trend observed since 2007 has 
continued, with the proportion of cases dropping slightly year on year from 39.8% in 2016 to 37.9% in 
2017. However, the reason for this decrease could be due to changes that took place in the national 
surveillance database in 2017 (see Treatment workbook Section T1.3.3 for further information). 
 
In 2017, 69.2% of cases were male, and the mean age was 34 years. The majority of cases were 
previously treated (75.8%). The proportion of problem heroin users who were new to treatment peaked in 
2009 at 34.4% but has decreased every year since. The majority (47.4%) were self-referred or referred by 
family/friends.  
 
Other opioids 
In 2017 methadone (prescribed or street) was the second most common other opioid reported, comprising 
6.9% of all treatment entrants for problem opiate use. Methadone was responsible for 3.1% of all cases 
treated. This was followed by codeine, accounting for 5.7% of all treatment entrants for problem opiate 
use. For further information on heroin and other opioids, see also TDI and Treatment workbook Sections 
T1.3.1 and T2.1. 
 
Treatment for problem opiate use is provided by both statutory and non-statutory services. Opiate 
substitution treatment (OST) is provided in specialised clinics or by specialised GPs. Other treatment 
provided includes counselling, social and occupational reintegration, psychiatric treatment, complementary 
therapy etc. For further information see Treatment workbook, Section T1.4. 
 
All opiates 
Data from TDI show that in 2016, just under half of all cases (46.9%) treated for problem drug use 
(excluding alcohol) were treated for opiates, similar to 2015 (47.6%). Of those treated for problem opiate 
use in 2016, heroin comprised the vast majority of cases (84.7%), similar to previous years.  However it 
should be noted that the results for opiates cases in 2016 could be due to changes that took place in the 
national surveillance database in 2017 (see Treatment workbook Section 1.3.3 for further information). 
 
Problem heroin use  
Problem heroin use comprised 39.8% of all cases treated in 2016. The proportion of cases treated for 
problem heroin use has fluctuated over the reporting period, rising from 59.7% in 2004 to a peak in 2006 of 
60.3%. In 2016, the downward trend observed since 2007 has continued, with the proportion of cases 
dropping slightly from 41.1% in 2015 to 39.8% in 2016.  However the reason for this decrease could be 
due to changes that took place in the national surveillance database in 2017 (see Treatment workbook 
Section T1.3.3 for further information). 
 
Since 2004, heroin has remained the most common illicit drug for which all cases have sought treatment. 
However, for cases new to treatment, the pattern changed in 2011, when cannabis replaced heroin as the 
most common problem drug reported by new entrants to treatment (also see Section 2 in the Treatment 
workbook). 
 
In 2016, 71.3% of cases were male, and the mean age was 34 years.  The majority of cases were 
previously treated (74.1%).  The proportion of problem heroin users who were new to treatment peaked in 
2009 at 34.4% but has decreased every year since. 
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Other opiates 
In 2016 methadone (prescribed or street) was the second most common other opiate reported, comprising 
6.8% of all treatment entrants for problem opiate use. This was followed by codeine, accounting for 4.8% 
of all treatment entrants for problem opiate use.  For further information on heroin and other opiates, see 
also TDI and Treatment workbook Sections T1.3.1 and T2.1. 
 
Treatment for problem opiate use is provided by both statutory and non-statutory services. Opiate 
substitution treatment (OST) is provided in specialised clinics or by specialised GPs. Other treatment 
provided includes counselling, social and occupational reintegration, psychiatric treatment, complementary 
therapy etc. For further information see Treatment workbook, Section 1.4 
 
T1.2.4 Synthetic Opioids 
 
At the time of publication there were no new data on synthetic opioids use in Ireland. 
T1.2.5 Injecting and other routes of administration 
 
Over half (55.0%) of cases reporting problem opioid use reported ever injecting (any drug, not necessarily 
the current main problem drug). Data from TDI show that in 2017, 30.8% of those treated for problem 
opioid use reported injecting as their primary route of administration. The proportions fluctuated over the 
period, from a peak of 48.4% in 2004 to its lowest level of 30.2% in 2010. For the next two years the 
proportion injecting increased to 41.1% in 2012 but has decreased slightly year-on-year since then to 33% 
in 2015. Heroin represents almost 100% of the opiate drugs injected. 
 
See Section T1.5.3 in Harms and Harm Reduction workbook for data on use of needle exchange 
programmes by injecting drug users in Ireland 
T1.2.6 Infectious diseases 
 
For information regarding drug-related infectious diseases in Ireland, see Harms and Harm Reduction 
workbook Section T1.3. 
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SECTION D. NEW PSYCHOACTIVE SUBSTANCES (NPS) AND OTHER DRUGS NOT COVERED 
ABOVE. 
 
T1.1 New Psychoactive Substances (NPS), other new or novel drugs, and less common drugs 
 
T1.1.1 Prevalence and trends in NPS use 
At the time of publication there were no new data on prevalence and trends in the use of NPS in Ireland. 
 
T1.1.2 Harms related to NPS use 
 
At the time of publication there were no new data on harms related to NPS use in Ireland. 
 
T1.1.3 Prevalence, trends and harms related to other drug use 
 
Since 2008 a very small number of cases presenting for treatment have reported a NPS other than a 
synthetic cannabinoid or cathinone) as their main problem drug through TDI. The type was usually 
unspecified. It should be noted that the type of NPS used by clients presenting to treatment is self-reported 
and so, even though the type of NPS may have been specified by a client, the actual drug is rarely tested 
by treatment centres. As a result, it is not possible to say with certainty that, for example, those NPS 
reported as synthetic cannabinoids or cathinones definitely fall into those categories. Among the cases 
reporting NPS (other than a synthetic cannabinoid or cathinone) as their main problem drug, there may be 
a number of which are a synthetic cannabinoid or cathinone, so the true number of synthetic cannabinoid 
or cathinone users may be under- or over-estimated. 
 
NPS first appeared in treatment data in 2008; before then they were not recorded as a separate category. 
The proportion of cases treated for these types of drugs peaked in 2010 at 0.4% of all treatment episodes, 
dropped to 0.06% in 2014, rose again slightly in 2015 to 0.1% before dropping to 0.01% in 2016, and 
remained at 0.01 in 2017. See also Section A T1.2.4 and Section B T1.2.4 above. 
 
 
Hypnotics and sedatives  
In 2017, hypnotics and sedatives were the fourth most common drug group treated (10.9%), as reported 
through TDI. The proportion of cases has risen consistently every year from 2006 from 2% to 11.2% in 
2014, with the trend remaining stable since then. In 2017, the main drug type included in this group were 
benzodiazepines (89.9%), similar to previous years. There were no changes to trends of the previous 
years. 
 
T2. Trends. Not relevant in this section. Included above. 
 
T3. New developments 
 
 
T3.1 New developments in the use of NPS and other drugs 
At the time of publication there were no new data on new developments in the use of NPS in Ireland. 
 
T4. Additional Sources of Information 
 
No new sources of information. 
 
T6. Sources and methodology 
 
T6.1 Sources  
 
Data on drug treatment in Ireland are collected through two national data collection tools – the Central 
Treatment List (CTL) and the National Drug Treatment Reporting System (NDTRS). 
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T6.2 Methodology 
 
Central Treatment List (CTL)  
The CTL is an administrative database to regulate the dispensing of methadone treatment. Established 
under Statutory Instrument No 225 (Minister for Health and Children 1998), it is a complete register of all 
patients receiving methadone (as treatment for opiate use) in Ireland. When a person is considered 
suitable for methadone detoxification, stabilisation or maintenance, the prescribing doctor notifies the CTL 
by completing an entry form, a unique number is allocated to the client and a treatment card is issued for 
clients when dispensed in community pharmacies. Numbers on the CTL are published annually by the 
HSE and Health Research Board (HRB).  
 
National Drug Treatment Reporting System (NDTRS)  
The NDTRS is a national epidemiological database which provides data on treated drug and alcohol 
misuse in Ireland. The NDTRS collects data from both public and private outpatient services, inpatient 
specialised residential centres and low-threshold services. For the purposes of the NDTRS, treatment is 
broadly defined as “any activity which aims to ameliorate the psychological, medical or social state of 
individuals who seek help for their substance misuse problems”. The NDTRS is a case-based, anonymised 
database. It is co-ordinated by staff at the Health Research Board (HRB) on behalf of the Department of 
Health 
 
T6.3 References 
 
Health Research Board. Irish National Focal Point to the European Monitoring Centre for Drugs and 
Drug Addiction (2017). Ireland: national report for 2016 - drugs. Health Research Board, Dublin. 
Available at http://www.drugsandalcohol.ie/25521/  
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European Monitoring Centre for Drugs and Drug Addiction 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a decentralised EU agency 
based in Lisbon.  The EMCDDA provides the EU and its Member States with information on the nature, 
extent, consequences and responses to illicit drug use. It supplies the evidence base to support policy 
formation on drugs and addiction in both the European Union and Member States.   
There are 30 National Focal Points that act as monitoring centres for the EMCDDA.  These focal points 
gather and analyse country data according to common data-collection standards and tools and supply 
these data to the EMCDDA. The results of this national monitoring process are supplied to the Centre for 
analysis, from which it produces the annual European drug report and other outputs. 
 
The Irish Focal Point to the EMCDDA is based in the Health Research Board.  The focal point writes and 
submits a series of textual reports, data on the five epidemiological indicators and supply indicators in the 
form of standard tables and structured questionnaires on response-related issues such as prevention and 
social reintegration.  The focal point is also responsible for implementing Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of new psychoactive substances. 
 
Acknowledgements 
Completion of the national focal point’s reports to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) depends on the support and cooperation of a number of government departments 
and statutory bodies. Among those to whom we would like to express our thanks are the staff of the 
following: 
 
Customs Drugs Law Enforcement, Revenue 
Department of Children and Youth Affairs 
Department of Education and Skills 
Drugs and Organised Crime Unit, An Garda Síochána 
Drugs Policy Division, Department of Justice and Equality 
Drugs Policy Unit, Department of Health 
Forensic Science Ireland 
Health Protection Surveillance Centre, Health Service Executive 
Hospital In-Patient Enquiry Scheme, Health Service Executive 
Irish Prison Service 
National Advisory Committee on Drugs and Alcohol, Department of Health 
National Social Inclusion Office, Primary Care Division, Health Service Executive 
 
We also wish to acknowledge the assistance of the coordinators and staff of local and regional Drug and 
Alcohol Task Forces, voluntary, community-based and other non-governmental organisations. 
 
We wish to thank our HRB colleagues in the Evidence Centre, National Drug Treatment Reporting 
System, the National Drug-related Deaths Index and the HRB National Drugs Library, all of whom make 
significant contributions to the preparation of the national report. 
